Sign In
Buy XFOR
$4.04
-0.0700 (-1.70%)
At Close: Jun 02, 2026
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
05:57pm, Monday, 16'th Feb 2026
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026
07:00am, Tuesday, 03'rd Feb 2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team wil
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 02'nd Feb 2026
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
01:01pm, Monday, 12'th Jan 2026
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
10:57am, Wednesday, 24'th Dec 2025
X4 Pharmaceuticals, Inc. (XFOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, XFOR's 50-day simple moving average crossed a
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia
09:09am, Monday, 01'st Dec 2025
X4 Pharmaceuticals is a single-asset biotech built around Mavorixafor. This is approved for WHIM in the US, and the next step is a label expansion for CN. XFOR's 4WARD Phase 3 trial in CN will be key.
X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
04:01pm, Wednesday, 05'th Nov 2025
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team wil
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
09:16am, Wednesday, 05'th Nov 2025
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $5.41 per share a year ago.
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 05'th Nov 2025
Company's strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announ
Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Price Target at $34.17
02:36am, Sunday, 26'th Oct 2025
Shares of X4 Pharmaceuticals, Inc. (NASDAQ: XFOR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five ratings firms that are covering the stock, MarketBeat reports. One
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
12:37am, Friday, 24'th Oct 2025
BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announ
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
04:01pm, Thursday, 23'rd Oct 2025
BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announ
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 22'nd Oct 2025
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
07:00am, Wednesday, 17'th Sep 2025
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in ad
